Citation: R v Pan Pharmaceuticals Pty Ltd [2008] NSWDC 221
Court: NSW District Court
Date: 19 September 2008
Judge(s): Nield DCJ
Background
Pan Pharmaceuticals Pty Ltd was an Australian pharmaceutical manufacturer and the successor company to Pan Laboratories Pty Ltd. It was listed on the Australian Stock Exchange in April 2001 and, before February 2003, held sponsorship over 1,660 therapeutic goods registered for export only with the Therapeutic Goods Administration (TGA).
The offending came to light in February 2003 when a Vietnamese pharmaceutical company queried the validity of a Certificate of a Pharmaceutical Product apparently issued by the TGA on Pan Pharmaceuticals' behalf. Investigators found that the certificate was false: the identifying number referred to a different sponsor and a different product entirely. Further investigation revealed a systematic pattern of conduct involving forged certificates used to export therapeutic goods to Vietnam.
Vietnam's Drug Administration permitted importation of Australian goods without full local registration, provided the goods were approved for domestic sale in Australia and authenticated by a valid TGA certificate. A number of Pan's export-only goods had never been approved for domestic Australian supply, making them ineligible for the certificates that were nonetheless presented to Vietnamese authorities. Pan Pharmaceuticals was placed into liquidation during the relevant period, and it was the company's liquidators who engaged with the criminal proceedings.
Legal Issues
- Whether Pan Pharmaceuticals should be convicted of knowingly using false documents, contrary to the Criminal Code Act 2005 (Cth)
- Whether Pan Pharmaceuticals should be convicted of dealing with counterfeit therapeutic goods, contrary to the Therapeutic Goods Act 1989 (Cth)
- What sentences, by way of fines, were appropriate for each of the 53 offences given the guilty pleas entered and the relevant sentencing considerations
Decision
Pan Pharmaceuticals entered guilty pleas to all 53 charges: multiple counts of knowingly using a false document and multiple counts of dealing with counterfeit therapeutic goods. The court accepted the pleas and proceeded to determine appropriate penalties for a corporate offender.
Nield DCJ found the offending to be serious and deliberate. The conduct involved the systematic production and use of forged TGA certificates to enable the export of therapeutic goods to Vietnam, a country that relied on Australian regulatory approvals rather than conducting its own independent assessment. The court noted that the false certificates undermined both Australia's regulatory framework for therapeutic goods and the trust placed in that framework by importing nations.
The court identified that, had the offender been a natural person, full-time custodial sentences would have been the only appropriate outcome for each offence. As a corporate entity in liquidation, only financial penalties were available. The court set starting fines of $1,000,000 per false document offence and $175,000 per counterfeit therapeutic goods offence, then reduced each by 20 per cent to reflect the utilitarian value of the guilty pleas. Applying the totality principle to avoid a disproportionate aggregate, the court adjusted the individual fines downward to arrive at a total penalty of $10,000,000 across all 53 offences.
On general deterrence, the court emphasised that deliberate and intentional flouting of Australia's therapeutic goods regulatory regime would not be tolerated. Specific deterrence was treated as irrelevant given the company's liquidation.
Orders Made
- Pan Pharmaceuticals convicted of all 53 offences to which it pleaded guilty
- For each offence of knowingly using a false document: a fine of $500,000
- For each offence of dealing with counterfeit therapeutic goods: a fine of $125,000
- Total aggregate fine: $10,000,000 (reflecting the totality principle)
Key Takeaways
- The District Court confirmed that corporate offenders are not immune from significant criminal sanction for systematic regulatory fraud, even where the company is in liquidation and specific deterrence is no longer relevant.
- Where a corporate defendant cannot be imprisoned, fines remain the primary sentencing tool, and the court will set starting points that reflect the gravity of deliberate regulatory offending before applying any discount for a guilty plea.
- A 20 per cent reduction in the starting fine was applied to each offence to reflect the utilitarian value of the guilty pleas.
- The totality principle applies to corporate sentencing: even where the arithmetic sum of individual fines would produce a very large figure, the court will adjust individual penalties to ensure the total reflects the overall criminality without becoming disproportionate.
- Australia's therapeutic goods export certification framework depends on the integrity of TGA-issued certificates, and countries such as Vietnam that rely on Australian regulatory approvals rather than conducting independent assessments are particularly exposed when that integrity is undermined.
Legislation and Cases Referenced
Legislation:
- Crimes Act 1914 (Cth)
- Criminal Code Act 2005 (Cth)
- Therapeutic Goods Act 1989 (Cth)
Cases: No cases were cited in the provided text of the judgment.